<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813956</url>
  </required_header>
  <id_info>
    <org_study_id>TCD11487</org_study_id>
    <secondary_id>20080206</secondary_id>
    <nct_id>NCT00813956</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether the neoadjuvant combination of gemcitabine, carboplatin,&#xD;
      and BSI-201 will cause a high percentage of triple negative breast cancer patients to achieve&#xD;
      a pathologic complete response prior to surgery.&#xD;
&#xD;
      Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess&#xD;
      characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been&#xD;
      fully elucidated, however based on experiments on tumor cells performed in the laboratory,&#xD;
      iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of&#xD;
      DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell&#xD;
      lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines.&#xD;
      Investigations into potential targets of iniparib and its metabolites are ongoing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard chemotherapy plus BSI-201</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine plus carboplatin plus BSI-201</intervention_name>
    <description>iv, 3 week cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  invasive breast cancer&#xD;
&#xD;
          -  stage I-IIIA disease&#xD;
&#xD;
          -  ER, PR, Her2/neu-negative status&#xD;
&#xD;
          -  no prior treatment for breast cancer&#xD;
&#xD;
          -  age 18 years of greater&#xD;
&#xD;
          -  normal renal, liver function&#xD;
&#xD;
          -  normal hematologic status&#xD;
&#xD;
          -  ECOG Performance status 0, 1&#xD;
&#xD;
          -  Evaluation by a surgeon to determine breast conservation eligibility&#xD;
&#xD;
          -  Women of childbearing potential must have a documented negative pregnancy test within&#xD;
             2 months of study trial entry and agree to birth control during the duration of the&#xD;
             trial therapy&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic breast cancer&#xD;
&#xD;
          -  Inoperable breast cancer, including Stage IIIB and IIIC&#xD;
&#xD;
          -  Tumor size less than 1 centimeter&#xD;
&#xD;
          -  Prior surgery, systemic therapy, or radiotherapy for the current cancer&#xD;
&#xD;
          -  Hormone receptor-positive breast cancer&#xD;
&#xD;
          -  Her2/neu-positive breast cancer&#xD;
&#xD;
          -  Any concurrent condition which in the investigator's opinion makes it inappropriate&#xD;
             for the patient to participate in the trial or which would jeopardize compliance with&#xD;
             the protocol&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Receipt of any investigational agents within 30 days prior to commencing study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Comprehensive Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PrECOG</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <disposition_first_submitted>February 17, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 17, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 17, 2016</disposition_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>triple negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Iniparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

